Amphetamine-related drugs, such as 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (METH), are popular recreational psychostimulants. Several preclinical studies have demonstrated that, besides having the potential for abuse, amphetamine-related drugs may also elicit neurotoxic and neuroinflammatory effects. The neurotoxic potentials of MDMA and METH to dopaminergic and serotonergic neurons have been clearly demonstrated in both rodents and nonhuman primates. This review summarizes the species-specific cellular and molecular mechanisms involved in MDMA and METH-mediated neurotoxic and neuroinflammatory effects, along with the most important behavioral changes elicited by these substances in experimental animals and humans. Emphasis is placed on the neuropsychological and neurological consequences associated with the neuronal damage. Moreover, we point out the gap in our knowledge and the need for developing appropriate therapeutic strategies to manage the neurological problems associated with amphetaminerelated drug abuse. ß
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Abbreviations: AC, adenylyl cyclase; AcbSh, nucleus accumbens shell; AcbC, nucleus accumbens core; cAMP, cyclic adenosine monophosphate; CNS, central nervous system; CPu, caudate putamen; CREB, cAMP responsive element binding protein; CSF, cerebrospinal fluid; CYP, cytochrome P450 enzymes; DA, dopamine; DAT, DA transporter; 5,7-DHT, 5,7-dihydroxytryptamine; L-DOPA, 3,4-dihydroxy-L-phenylalanine; DOPAC, 3,4-dihydroxyphenylacetic acid; DPCPX, dipropylcyclopentylxanthine, adenosine A1 receptor antagonist; ERK, extracellular-signal-regulated kinase; FDA, Food and Drug Administration; fMRI, functional magnetic resonance imaging; GBR12909, vanoxerine, antagonist of DAT; GFAP, glial fibrillary acidic protein; GLU, glutamate; GSH, glutathione; HHMA, 3,4-dihydroxymethamphetamine; 5-HIAA, 5-hydroxyindoleacetic acid; HPA, hypothalamus-pituitary-adrenal axis; 5-HT, serotonin; HVA, homovanillic acid; HPLC, high-performance liquid chromatography; JAK, Janus kinase; JNK, c-Jun Nterminal kinases; ICV, intracerebroventricular; IL, interleukin; Mac-1, macrophage-1 antigen; MAO-B, monoamine oxidase type B; MAPK, mitogen-activated protein kinase;
a-MeDA, a-methyldopamine; MDA, 3,4-methylenedioxyamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; METH, methamphetamine; MK-801, dizocilpine, NMDA receptor antagonist; MOR-1, m opioid receptor; a-MPT, alpha-methyl-para-tyrosine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MRI, magnetic resonance imaging; NA, noradrenaline; NAC, N-acetylcysteine; NET, NA transporter; 7-NI, 7-nitroindazole; NMDA, N-methyl-D-aspartate; NO, nitric oxide; 3-NT, 3-nitrotyrosine; nNOS, neuronal NO synthase; 6-OHDA, 6-hydroxydopamine; PD, Parkinson's disease; PET, positron emission tomography; PKC, protein kinase C; ROS, reactive oxygen species; RNS, reactive nitrogen species; SCH23390, dopamine D 1 receptor antagonist; SERT, 5-HT transporter; SN, substantia nigra; SNc, SN pars compacta; SOD, superoxide dismutase; SPECT, single photon emission computed tomography; TH, tyrosine hydroxylase; TNF, tumor necrosis factor; VMAT2, vesicular monoamine transporter; VTA, ventral tegmental area.
